



About the “Empowering the Lymphatics: Unleashing the Potential of Biologics that Target the Immune System” Panel Participants:

Brian Cooley

Senior Vice President, Corporate Communications and Investor Relations, Sorrento Therapeutics
Head of SOFUSA Lymphatic Drug Delivery Division

Mr. Cooley is an accomplished pharmaceutical executive with more than 35 years of experience and a track record of bringing novel pharmaceutical and medical device solutions to market. Before joining Sorrento, Brian was CBO for Kimberly-Clark Innovation, where he ran business strategy for Sofusa, which led to the eventual sale of the Sofusa Lymphatic Delivery Platform to Sorrento Therapeutics in June 2018.

Mr. Cooley has also led significant business development, in-licensing, and integration efforts, both internationally and in the U.S. These included multiple manufacturing, co-development, and JV deals in Europe, Middle East, and Africa which helped grow market share from 10% to 45% in these regions.

As head of drug delivery at Eli Lilly, Mr. Cooley led the transformation of Lilly’s insulin device business into a patient-centered drug development group covering diabetes, autoimmune, and oncology pipelines, and he was also responsible for discovery and evaluation of external drug delivery technologies. He initiated and led the \$400MM Lilly-Amylin deal to co-develop and commercialize the first GLP-1 agonist, paving the way for a \$20B category in diabetes and obesity.

As Chief Business Officer for cloud-based start-up, Samepage Health, Mr. Cooley designed, developed, and successfully launched a cloud-based technology platform to IDN’s (Integrated Delivery Networks) and health systems. During his early career in the U.S. and 10 years in Europe, he led multiple new product launch efforts for successful pharmaceutical brands such as Humalog, Byetta, Actos, Taltz, and MYCAPSSA.

Mr. Cooley earned a B.A. in Liberal Arts from DePauw University, and a B.S. in Chemical Engineering from Purdue University.

Chris Jeffers, Ph.D., J.D.

Chief Executive Officer, Mayflower BioVentures

Chief Executive Officer, Hibiscus BioTechnology

Chris is a 25+ year veteran of healthcare and biotech. Beginning his career Chris ran clinical laboratories for the U.S. Air Force and civilian hospitals in the early 90's. Since then, he has held various roles including CEO, General Counsel, Vice President of Drug Discovery, Managing Director and has served as outside counsel to hundreds of life science companies ranging from big pharma to individual inventors.

Chris is the co-Founder and CEO of Hibiscus BioTechnology, a Venture Studio, and is the CEO of Mayflower BioVentures – a collaboration between Hibiscus and the Mayo Clinic focused on the formation of new cell and gene therapy companies. Before co-founding Hibiscus Chris was a partner in the Washington, DC office of Mintz Levin, where he led a multidisciplinary team specializing in representing biotech and pharma companies in complex corporate, financing and commercial transactions as well as general business advising.

Chris received his Ph.D. training in Biochemistry and Biophysics at Rice University and the University of Houston, where he was a National Institutes of Health Predoctoral Fellow. Following his Ph.D. training Chris was an NIH Postdoctoral Fellow at The Johns Hopkins University School of Medicine where he studied the structure of the Cystic Fibrosis Transmembrane Conductance Receptor (CFTR). In addition, Chris obtained his law degree from Georgetown University. Bringing years of startup experience to Hibiscus Chris was the founder of FirstStage Bioventures, Seguro Surgical, EncephRx and Camden Pharmaceuticals, and was the General Counsel and V.P. of Drug Discovery at Alba Therapeutics. In addition to serving as outside General Counsel to numerous biotech companies including Viela Bio and NexImmune, Chris holds adjunct faculty appointments in the School of Business and Whiting School of Engineering at Johns Hopkins University.

Roel N. Querubin, MD

Atlanta Research Center for Rheumatology and Marietta Rheumatology Associates

Dr. Querubin is a practicing rheumatologist in the Atlanta area who is dedicated to the diagnosis and management of Musculoskeletal Disease. His special interests are the Inflammatory Arthropathies, which include the Connective Tissue Diseases and Spondyloarthropathies. He remains active in Rheumatology Research and is one of the Principal Investigators in the Division of Research at Marietta Rheumatology. His Clinical Research Trial experience includes the study of therapies for Rheumatoid arthritis, Systemic Lupus, Psoriatic arthritis, and Ankylosing Spondylitis. He has written articles and research publications for National Rheumatology Journals and has presented for National Medical Meetings.

Dr. Querubin received his M.D. at the Medical College of Georgia and completed a three-year Internal Medicine Residency at the Atlanta Medical Center prior to conducting his Rheumatology Fellowship at the Emory University School of Medicine. He is an honors graduate from the Georgia Institute of Technology, where he received a B.S. in Applied Biology. Dr. Querubin is a member of the American College of Rheumatology, American Medical Association, Metro Atlanta Rheumatology Society, and the Philippine American Medical Association of Georgia.

Russell F. Ross, Ph.D.

Chief Technical Officer, Sofusa

Rusty Ross leads the development and commercialization of novel lymphatic directed therapies for rheumatoid arthritis and oncology including melanoma and non-Hodgkin's lymphoma. Dr. Ross is also the inventor of the Sofusa lymphatic delivery platform redefining therapies for immune system diseases by treating targets in the lymph nodes versus more traditional systemic approaches. Prior, Dr. Ross spent 22 years at Kimberly-Clark in several research and leadership positions in both the consumer and professional businesses. He received his doctorate from the University of Wisconsin and has been awarded more than 73 patents and published 9 peer reviewed papers.

Mike A. Royal, M.D.

Chief Medical Officer, Sorrento Therapeutics

Dr. Royal, Chief Medical Officer at Sorrento Therapeutics, is a pharmaceutical executive with 20 years of clinical development and medical affairs. Recently, he was the Chief Medical Officer of Suzhou Connect Biopharmaceuticals and, prior to that, Concentric Analgesics. He rejoins Sorrento where he was previously EVP, Clinical Development and Regulatory Affairs in 2016. He has been responsible for or instrumental in several successful NDAs, including NCEs, 505(b)(2)s and ANDAs. Dr. Royal is board certified in internal medicine, pain medicine, anesthesiology with additional qualifications in pain management, addiction medicine and legal medicine. He has been an Assistant Professor of Medicine at the Uniformed Services University of Health Sciences, Assistant Professor of Anesthesiology/Critical Care Medicine at the University of Pittsburgh Medical Center, and an Adjunct Professor at University of Oklahoma and University of California San Diego. Dr. Royal holds an M.D. from UMass Chan School of Medicine, an M.B.A. from New York University's Stern School of Business, a J.D. from University of Maryland Francis King Carey School of Law and a B.S. in Synthetic Organic Chemistry from Massachusetts Institute of Technology. He has published extensively with over 190 book chapters, peer reviewed articles and abstracts/posters; and has been an invited speaker at national and international meetings

Vibeke Strand, M.D.

Adjunct Clinical Professor, Div. of Immunology & Rheumatology, Stanford University School of Medicine

Dr. Strand has more than 40 years of clinical rheumatology expertise. She is currently an adjunct clinical professor in the Division of Immunology and Rheumatology at Stanford University School of Medicine, since 1993; having taught at University of California, San Francisco (UCSF) since 1981. Previously, Dr. Strand has been in subspecialty practice, a clinical investigator, and a senior director of clinical research at three pharmaceutical / biotechnology companies. Since 1991, Dr. Strand has led a consulting practice offering clinical research and regulatory strategy expertise in rheumatologic diseases to biotech and pharma. During the past 30 years, she has participated in the development of most of the approved biologic and targeted synthetic agents in rheumatoid arthritis, psoriatic arthritis, and Systemic Lupus Erythematosus, and studied many promising agents in spondyloarthritis, osteoarthritis and gout.

Dr. Strand completed an internal medicine primary care residency at Michigan State University and a Rheumatology/Immunology fellowship at UCSF, where she received her M.D. Dr. Strand earned her B.A. in Zoology & Sociology/Anthropology from Swarthmore College.

